The Azd0466 AstraZeneca trial is expanding indications in phase 1 clinical trials globally as announced in February
AstraZeneca’s significantly expanded clinical program for AZD0466 will include a multi-centre global Phase 1 study in acute leukaemias.
This updated program will expedite development of AZD0466 with the objective of obtaining regulatory approval for specific indications of high unmet clinical need and this represents AstraZeneca's major focus.
SPL Price at posting:
$1.69 Sentiment: Buy Disclosure: Held
